COO Nov 2024 97.500 put
| Previous close | 9.80 |
| Open | 9.80 |
| Bid | 7.80 |
| Ask | 12.00 |
| Strike | 97.50 |
| Expiry date | 2024-11-15 |
| Day's range | 9.80 - 9.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
ZacksThe Cooper Companies (COO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for The Cooper Companies (COO) give insight into how the company performed in the quarter ended April 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksThe Cooper Companies (COO) Surpasses Q2 Earnings Estimates
The Cooper Companies (COO) delivered earnings and revenue surprises of 2.41% and 0.56%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCooperCompanies Announces Second Quarter 2024 Results
SAN RAMON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2024. Revenue increased 7% year-over-year to $942.6 million. CooperVision (CVI) revenue up 8% to $635.9 million, and CooperSurgical (CSI) revenue up 6% to $306.7 million.GAAP diluted earnings per share (EPS) of $0.44, up $0.24 or 122% from last year's second quarter.Non-GAAP diluted EPS of $0.85
